Main aspects to consider for Gene Therapies development

The market for regenerative medicines, and more specifically that of gene therapy, has grown enormously in the last decade. There are many ways to do gene therapy, one of the most common and most effective being the delivery of healthy genes using viral vectors.

Viral vectors are genetically modified viruses which are entirely manufactured in the lab. However, the fact that they are biological agents often makes their production challenging.

Fine-tuning of the manufacturing process is key to the success of this type of therapy, which is determined not only by the quantity of the product, but, more importantly, by its quality and purity.

In this panel we will address different aspects of lentivirus-based gene therapy: from manufacturing to their application in human.

Moderator:

- **Gurutz Linzasoro**, CEO, VIVEbiotech (Spain)

Speakers:

- **Massimo Dominici**, MD, Scientific Founder, Rigenerand (Italy)
- **Tol Trimborn**, CEO. CellPoint (The Netherlands)
- **Natalia Elizalde**, PhD, BD Director, VIVEbiotech (Spain)